The global immune checkpoint inhibitors market is expected to grow at a CAGR of 19.48% during the forecast period. Major vendors in the global immune checkpoint inhibitors market include AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck Sharp & Dohme, and Pfizer among others. As per the latest market research report published by Technavio, the immune checkpoint inhibitors market size will grow by USD 24.14 billion during 2019-2023. Get the free sample report below for the detailed information.
Download the free sample report @ http://bit.ly/2DPKFfT
Immune checkpoint inhibitor therapeutics is one of the most reliable therapeutic treatment options for the treatment of cancer. Hence, many companies are associating for developing and marketing these drugs. For instance, Merck collaborated with F-star, to develop and commercialize five bispecific immune-oncology antibodies. Pfizer collaborated with the National Cancer Institute, to study immune-therapeutic candidates targeting multiple cancers.
Similarly, Bristol-Myers Squibb associated with Novartis, to study OPDIVO in combination with targeted therapies from Novartis to treat NSCLC. Such strategic alliances and partnerships help to reach out a larger geographical area, expand the product portfolio, and result in higher ROI, as these products are co-developed and marketed. Hence, the vendors in the market are expected to continue exploring strategic ways to tap significant opportunity, thereby driving the global immune checkpoint inhibitors market growth. To know the complete and in-depth analysis and forecast of this market get the complete report by clicking the link below.
Get the Complete Report @ http://bit.ly/2LpA2ES
Comments